Imaging recommendation · Chest

New respiratory symptoms on cytotoxic / targeted therapy, suspected drug-induced pneumonitis

Q: What's the alternative imaging for new respiratory symptoms on cytotoxic / targeted therapy, suspected drug-induced pneumonitis when infection exclusion (immunocompromised)?

CT — CT Chest with IV + BAL (iv contrast).

Recommended: HRCT Chest without contrast is the preferred imaging study for new respiratory symptoms on cytotoxic / targeted therapy, suspected drug-induced pneumonitis. Bleomycin, methotrexate, amiodarone, immune checkpoint inhibitors, EGFR-TKIs common offenders.

Recommended study

HRCT Chest without contrast

CT No contrast Preferred Chest Acute inpatientOutpatient Reviewed 2026-05

Bleomycin, methotrexate, amiodarone, immune checkpoint inhibitors, EGFR-TKIs common offenders.

If the default doesn't apply

Infection exclusion (immunocompromised)

CT CT Chest with IV + BAL IV contrast

Watch-outs

Stop the drug + steroids

Definitive management is drug withdrawal; high-dose steroids for moderate-severe.

Immunotherapy-related pneumonitis

Grade-based management per oncology / pulm; severe cases require ICU + steroids ± infliximab.

Pearls

Common patterns: NSIP, OP/COP, hypersensitivity, eosinophilic, diffuse alveolar damage.
Pneumotox.com is a useful resource for specific drug patterns.
Amiodarone lung: high-attenuation peripheral consolidation (iodine content).